Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VUM02
- Development stage
- Phase 2
- Lead developer
- 武汉光谷中源药业
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
VUM02 is an allogeneic cell therapy product comprising culture-expanded mesenchymal stem cells derived from human umbilical cord tissue. It is cryopreserved with a cell concentration of 5 x 10^6 cells/mL. The product is being developed for multiple indications including idiopathic pulmonary fibrosis (IPF) and steroid-refractory acute graft-versus-host disease (SR-aGvHD). As a mesenchymal stem cell therapy, it likely functions through immunomodulatory and anti-inflammatory mechanisms.
- Brand names
- VUM02 InjectionVUM-02 InjectionVUM 02 Injection
- Other names
- Human Umbilical Cord Tissue-derived Mesenchymal Stem Cells InjectionhUCT-MSChuman umbilical cord-derived mesenchymal stromal/stem cells
Beyond the preview
Go deeper on VUM02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VUM02.